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Abstract 
Traceable truncated Neuropeptide Y (NPY) analogues with Y1 receptor (Y1R) affinity and 
selectivity are highly desirable tools in studying receptor location, regulation and biological 
functions. A range of fluorescently labelled analogues of a reported Y1R/Y4R preferring ligand 
BVD-15 have been prepared and evaluated using high content imaging techniques. One 
peptide, [Lys2(sCy5), Arg4]BVD-15, was characterised as an Y1R antagonist with a pKD of 7.2 
measured by saturation analysis using fluorescent imaging. The peptide showed 8-fold lower 
affinity for Y4R (pKD = 6.2) and was a partial agonist at this receptor. The suitability of 
[Lys2(sCy5), Arg4]BVD-15 for Y1R and Y4R competition binding experiments was also 
demonstrated in intact cells. The nature of the label was shown to be critical with replacement 
of sCy5 by the more hydrophobic Cy5.5 resulting in a switch from Y1R antagonist to Y1R 
partial agonist. 
 
 
 
 
 
  
Introduction 
Neuropeptide Y (NPY) is a 36-amino acid, C-terminal amidated polypeptide first isolated from 
porcine brain by Tatemoto’s group in 1982.1 It is a member of the NPY peptide family along 
with pancreatic polypeptide (PP, isolated in 1983)2 and peptide YY (PYY, isolated in 1980)3, 
which both share a high degree of homology in amino acid sequence. The physiological 
functions of NPY are mediated by Y receptors, belonging to the rhodopsin-like Gi coupled G-
protein coupled receptor (GPCR) family and four subtypes, Y1R, Y2R, Y4R and Y5R have been 
identified in humans.4-6 Y1R is expressed abundantly in both central and peripheral sympathetic 
nervous systems, and the NPY/Y1R signalling cascade is implicated in various physiological 
responses, including regulation of feeding behaviour,7, 8 stimulation of ethanol intake,9, 10 
vasoconstriction11, 12 and initiation of anxiety and depression.13, 14 In addition, breast 
carcinomas, including primary tumours and lymph node metastases, have also been found to 
over-express Y1R.
15 This suggests that Y1R may be responsible in tumour proliferation, 
apoptosis, metastasis and angiogenesis.16  
With Y1R being a potential drug target, traceable high affinity Y1R ligands are highly desirable 
tools for studying the localisation, regulation and function of this receptor. Lys4(sCy5)-NPY 
was shown to be an agonist of Y1R, Y2R and Y4R receptors, and of utility in the development 
of FACS-based functional assays of complex cell-based assay systems.17 Another approach 
has been to derive fluorescent or radiolabelled analogues of the Y1R arginamide antagonist 
series (BIBP3226, BIBO3304),18 including pyridinium and cyanine based BIBP3226 
derivatives suitable for fluorescent imaging.19, 20. An alternative starting point has made use of 
smaller NPY derived peptide ligands, such as the competitive Y1R antagonist / Y4R agonist 
BVD-15 (or BW1911U90), a nonapeptide modified from the NPY C-terminal fragment ( 
Figure 1).21 This peptide has been amenable to conjugation with a variety of radiolabels and 
fluorophores. In particular, Guérin et al. showed that the Ile4 residue could be substituted by 
conjugated Lys to incorporate DOTA, NOTA or fluorine moieties,22, 23 and we extended this 
result to include a rhodamine fluorophore.24 No less notably, the Lys4 substitution itself 
resulted in increased affinity,23 and other basic residues were also well tolerated.24 This 
prompted us to examine such analogues with Pro3 as a point of conjugation and we have 
recently described propargyloxyproline containing Lys4- and Arg4-BVD-15 that could 
incorporate rhodamine B and 7-aminocoumarin fluorophores.25 The tyrosine at the 5-position 
has been also shown to be capable of replacement with a conjugate group.26 
Noting that the position and nature of the conjugated group and its linkage could have a 
significant influence on the pharmacology of the resulting peptide, here we have examined the 
2- and 4-position as the points of conjugation, and identified a number of potent novel 
fluorescently labelled Y1R-targeting peptidic ligands. We have explored the utility of one of 
these and found it to be an excellent reagent for performing fluorescent imaging of recombinant 
cells transfected with Y1R or Y4R, allowing the development of receptor binding studies in 
intact living cells. 
 
Figure 1: The amino acid sequence of BVD-15 scaffold and reported conjugated amino acid replacements. 
FBz = 4-fluorobenzoyl, Rtp = rhodamine B-triazolyl-proline, Ctp = coumarin-triazolyl-proline, Bpa = 4-
benzoylphenylalanine. 
 
Ile-Asn-Pro-Ile-Tyr-Arg-Leu-Arg-Tyr-NH
2
 
Lys, Lys(DOTA) 
Lys(NOTA), Lys(RhB) 
Lys(FBz) 
Rtp, Ctp Bpa 
Results and Discussion 
Chemistry 
We began by expanding our pool of conjugate precursors to include a variety of rhodamine B 
(RhB) conjugates (Figure 2), taking advantage of the capacity to generate different linkers 
from a common, inexpensive precursor,27 as well as two cyanine dyes (Figure 2) Cy5.5 and 
sulfo-Cy5 (sCy5). We extended the types of conjugates included at Lys4, but also encompassed 
substitutions at Asn2. While a lysine residue at the 2-position had been shown to be detrimental 
to Y1R activity,
23 the influence on subsequent conjugation had not been tested. 
The synthesis of the conjugated BVD-15 analogues was achieved by one of three distinct 
methods. While all peptide backbones were prepared by adapting standard Fmoc-based solid 
phase peptide synthesis (SPPS) strategy, both solid and solution phase side-chain labelling 
were attempted. To facilitate chemoselective derivatisation at the 2-position, the 4-position was 
substituted by an Arg residue, which retains high affinity for Y1R receptors.
25 
 
Figure 2: Fluorescent dye conjugates utilised in this study. 
In the first instance, linear peptides were synthesised with N-terminal Fmoc protection and 
amide coupling in solution was achieved using carboxyl-functionalised fluorophores, followed 
by Fmoc-deprotection to yield the target peptides (analogues A, D, F and H, using Method 1 
in Scheme 1. In Method 2, selective ε-amine modification on solid phase was achieved by 
incorporating ε-Mtt-protected Lys as an orthogonal protection. The Mtt group was selectively 
cleaved off by treating with 25% HFIP and 5% TIPS, and then the Cy5.5 fluorophore was 
coupled as an N-succinimidyl ester. The N-terminal Fmoc group was removed by 20% 
piperidine prior to the final acidolytic cleavage, giving analogues E and G. In order to prepare 
analogues B and C where conjugates are linked by the 1,2,3-triazole group, Fmoc-Lys(azide)-
OH was incorporated at the 4-position. Labelling was then achieved by solution phase CuAAC 
reaction using the alkyne-containing RhB-2 and RhB-3, in presence of CuSO4 and sodium 
ascorbate as the catalysts (Method 3).25 The synthesised analogues with their analytical data 
are summarised in Table 1. 
 
 
 
Scheme 1: Fluorescent labelling of BVD-15 analogues. Reagents and Conditions: i. fluorophore-COOH (1.2 
eq.), PyClock (2 eq.), NMM (12 eq.), DMF, overnight (Note that for E and G, Cy5.5, was coupled as an N-
succinimidyl ester); ii. Piperidine (20%) in DMF, 5 min×2; iii. HFIP (25%) and TIPS (5%) in DCM, 30 min; 
iv. TFA-TIPS-DMB (92.5%:2.5%:5%), 3 h; v. RhB-alkyne (2 eq.), CuSO4 (0.5 eq.), THPTA (2.5 eq.), 
aminoguanidine (25 eq.), sodium ascorbate (25 eq.), DMSO 2% in potassium phosphate buffer (0.1 M, pH 
= 7.4), 1 h. 
Table 1: Fluorescently labelled BVD-15 analogues and their analytical data 
Code Sequence Labelling 
Method 
MW 
(Calc.) 
ESI-MS 
m/z a 
LC/MS RT. 
(min) b 
HPLC purity 
(%) 
A INPK(RhB-1)YRLRY-NH2 1 1815.2 605.9 10.24c 93 
B INP(K-N3-RhB-2)YRLRY-NH2 3 1839.3 613.9 13.42 99 
C INP(K-N3-RhB-3)YRLRY-NH2 3 1867.3 623.3 13.58 99 
D IK(RhB-1)PRYRLRY-NH2 1 1857.3 620.1 13.09 99 
E INPK(Cy5.5)YRLRY-NH2 2 1786.5 596.6 14.12d 94 
F INPK(sCy5)YRLRY-NH2 1 1859.3 621.2 12.72 98 
G IK(Cy5.5)PRYRLRY-NH2 2 1829.3 610.6 14.11d 99 
H IK(sCy5)PRYRLRY-NH2 1 1901.3 635.4 12.06 98 
a. ESI-MS base peak corresponds to [M+3H]3+. 
b. HPLC retention time using a Phenomenex Luna C-8 column (100Å, 3µm, 100×2.00mm). The 
gradient is composed of 100% H2O (0.1% TFA) for 4 min, 0-60% acetonitrile in H2O (0.1% TFA) 
over 10 min, and isocratic 60% acetonitrile in H2O (0.1% TFA) for 1 min. 
Detection wavelength = 214 nm. 
c. For analogue A, the gradient is composed of 100% H2O (0.1% TFA) for 4 min, 20-100% acetonitrile 
in H2O (0.1% TFA) over 10 min, and isocratic 100% acetonitrile (0.1% TFA) for 1 min. 
d. For analogue E and G, the gradient is composed of 100% H2O (0.1% TFA) for 4 min, 0-80% 
acetonitrile in H2O (0.1% TFA) over 10 min, and isocratic 80% acetonitrile (0.1% TFA) for 1 min. 
Pharmacological analysis of NPY analogues 
We examined the functional properties of the BVD-15 analogues as antagonists of NPY-
induced Y1R engagement with β-arrestin2, a GPCR effector protein involved in G protein 
independent signalling and agonist induced receptor desensitisation and internalisation.28 This 
assay gives a strong functional readout consistent with other second messenger assays, and the 
limited receptor reserve allows discrimination of agonist efficacy via changes in Rmax as 
compared to standard second messenger assays.20, 21, 28-30 Unlabelled [Lys4]BVD-15 23, 24 
behaved as a competitive reversible antagonist of NPY stimulated responses, as indicated by 
Schild analysis (Figure 3A) with a pA2 of 7.5, and all but one of the labelled ligands showed 
comparable high affinity antagonism. pKb values were calculated from NPY concentration 
response curve shifts in the presence of a single antagonist concentration (100 nM or 300 nM; 
Figure S1), and ranged from 6.9 to 7.9 with the rhodamine-linked triazole compound B 
showing highest affinity (Table 2). Of the four cyanine labelled derivatives, three were 
antagonists (Table 2) with compound H [Lys2(sCy5), Arg4]BVD-15 showed highest affinity, 
and shared the surmountable antagonist characteristics of [Lys4]BVD15 (Figure 3B). 
Interestingly, substitution of the sCy5 fluorophore for Cy5.5 at the same 2-position led to 
compound G showing partial agonism in the Y1R arrestin recruitment assay, with a pEC50 of 
7.04 ± 0.19 and a maximal response of 52.8 ± 4.8% compared to that elicited by 1 µM NPY (n 
= 3; Figure S2). In contrast, analogues E, F (both cyanine labelled at 4-position) and H showed 
no agonism at concentrations up to 1 µM. 
 
 
Figure 3: Surmountable antagonism of NPY stimulated Y1R activation by unlabeled [Lys4]BVD15 (Panel 
A) and sCy5-labelled derivative H (Panel B). Stably transfected HEK293 Y1R-β-arrestin2 cells were 
pretreated for 30 min with the antagonist peptide at the indicated concentrations, prior to 1 h NPY 
stimulation. β-arrestin2 recruitment was quantified by high content imaging complementation assay as 
described in materials and methods. Pooled data from 5 (A) or 4-7 experiments (B), globally fitted to obtain 
NPY pEC50 estimates, were used for Schild analysis in the right hand panels. These derived pA2 affinity 
estimates of 7.53 (analogue A) and 7.56 (analogue H) and respective slopes of 0.95 and 0.93, indicative of 
competitive reversible antagonism. 
Table 2: Affinity estimates for BVD-15 analogues derived from functional measurements or [125I]PYY 
competition binding. 
Code Sequence pKb pKi (±SEM) 
[Lys4]BVD-15 24 INPKYRLRY-NH2 7.5±0.1 8.6±0.1  
A INPK(RhB-1)YRLRY-NH2 7.6±0.2 9.5±0.2 
B INP(K-N3-RhB-2)YRLRY-NH2 7.9±0.2 9.6±0.1 
C INP(K-N3-RhB-3)YRLRY-NH2 7.6±0.2 9.4±0.1 
D IK(RhB-1)PRYRLRY-NH2 6.9±0.4 9.2±0.1 
E INPK(Cy5.5)YRLRY-NH2 7.3±0.1 8.4±0.2 
F INPK(sCy5)YRLRY-NH2 7.3±0.1 N.D. 
G IK(Cy5.5)PRYRLRY-NH2 agonist* 8.8±0.3 
H IK(sCy5)PRYRLRY-NH2 7.5±0.2 9.4±0.1 
* pEC50 = 7.0 ± 0.2, partial agonist (Figure S2). 
N.D. = not determined 
pKb estimates derived from pooled data using the Y1R-β-arrestin2 recruitment assay presented in 
Figure S1 (n = 4 or greater).  For comparison, pKi estimates (n = 3, except compound B n =2) are 
derived from [125I]PYY binding studies in Y1R-GFP membranes, performed under low sodium 
conditions in the absence of guanine nucleotides. 
We screened the fluorescent BVD-15 analogues for their ability to specifically label 293TR 
cells stably expressing the GFP-tagged Y1R. In plate-reader based imaging assays, RhB 
labelled derivatives (e.g. A, Figure 4) exhibited specific Y1R receptor binding, predominantly 
localised to the plasma membrane that was inhibited by NPY and the non-peptide Y1R 
antagonist BIBO3304. Cy5.5 analogues (E, G) displayed significant non-specific binding in 
addition to cellular labelling and were not pursued further. However, compound H displayed 
specific plasma membrane labelling of Y1R-GFP cells at concentrations as low as 1 nM 
(Figure 5A), and specific binding was fully inhibited by unlabelled competitors such as NPY 
or BIBO3304.  
Peptide H was therefore chosen to develop a plate-reader imaging based Y1R binding assay, 
using living whole cells. Peptide H displayed fluorescence consistent with the sCy5 labelling, 
with excitation and emission maxima at 653 nm and 667 nm respectively, and a relative 
quantum yield of 127% compared to sCy5-NHS alone (Supplementary Fig. 4). Based on 
optimised incubation conditions of 30 min at 37°C, saturation analysis demonstrated one site 
binding and derived a Y1R pKD for H of 7.16 ± 0.06 (n = 4) (Figure 5B), an estimate of affinity 
that was not significantly different from the pKb derived by functional analysis (Figure 3).  
Furthermore, initial BIBO3304 competition data compared a family of curves at different H 
concentrations (1 nM, 10 nM and 100 nM), yielding BIBO3304 pIC50 values of 9.06 ± 0.07, 
8.69 ± 0.07 and 8.31 ± 0.07 respectively (n = 4, Figure 5B). The proportionate shift in 
competing ligand IC50 was consistent with equilibrium conditions and the Cheng-Prusoff 
relationship. Additional affinity estimates for BIBO3304 (pKi = 8.9) and H (pKi = 7.3) 
determined by this method were consistent with our other whole cell data.   
 
Figure 4: Cellular labelling of Y1R-GFP by [Lys4(RhB)]BVD-15 (A). 293TR Y1R-GFP cells were 
incubated for 30 min at 37ºC with 10 nM A in the absence (control) or presence of 100 nM NPY or 100 nM 
BIBO3304.  Representative IX Micro images (from one of 3 experiments) of GFP (left) or RhB fluorescence 
(centre) are indicated, demonstrating extensive cell surface labelling using ligand A and co-localisation with 
the GFP-tagged Y1R.  
 
 Figure 5: Y1R binding assays using sCy5 labelled analogue H. Images from the IX Ultra platereader (Panel 
A, 400×400 pixels from original 1000×1000 acquisition) show binding of 10 nM H (red channel) to live 
293TR Y1R-GFP cells in the absence or presence of different NPY or BIBO3304 concentrations (30 min, 
with Y1R-GFP images (green) also presented for comparison. Saturation analysis (Panel B) was performed 
in the absence (Total) or presence of 1 M BIBO3304 (example experiment representative of 4). Pooled 
competition binding data (Panel C-E, at least 3 experiments) were derived from granularity analysis of the 
ligand images, normalised to total specific binding (100%). In C, BIBO3304 competition curves were 
performed at three H concentrations; the plot of the BIBO3304 IC50 versus ligand concentration (inset) 
provides additional Ki affinity estimates for both BIBO3304 and H quoted in text (see Materials and 
Methods). pKi estimates were also obtained for a range of agonist peptides (Panel D) and antagonists (Panel 
E), as indicated in Table 4. 
Peptide H was employed in the study of a range of known Y receptor agonists, antagonists as 
well as a series of analogues prepared in related studies (Table 3).29, 31 The expected Y1-like 
pharmacology in the competition assay was observed for agonist peptides (Figure 5D; NPY = 
[Leu31, Pro34]NPY ≥ PYY > PYY3-36 = PP), as previously described for many Y1 receptor 
systems,32 and also antagonists, such as the dimeric peptide 1229U91.29 The order of affinity 
based on pKi values from these experiments was consistent with [125I]PYY binding assays for 
representative ligands performed in Y1R-GFP cell membranes (and previously described data 
from Y2Y4 receptor knockout mice).
29 For the non-peptide antagonist BIBO3304 there was 
good correspondence between affinities measured in these formats, and also functional 
measurements previously reported.28 For the peptide ligands the actual pKi values for the whole 
cell assays were consistently lower than for membrane based assays (Table 4). The reason for 
this discrepancy is not obvious, but note that there is a closer correlation between the 
competition binding (pKi) and the functional antagonism in the whole cell system. The 
difference may be due to the buffer conditions in routine Y receptor membrane binding assays 
(low sodium and absence of guanine nucleotides) that are designed to promote the high affinity 
ternary receptor complex, and maximize radiolabelled agonist peptide binding.33 The non-
physiological buffer cation concentrations might also directly affect peptide ligand binding to 
the receptor. Thus one of the important advantages of our measurements using fluorescent 
antagonist binding to whole cells, in physiological buffer, is that the affinities obtained should 
closely correspond to observations from functional data, particularly for agonists. Indeed the 
estimates of agonist affinity by this route (
 
Figure 5D) do closely correspond with their potencies in Y1R-arrestin recruitment assay 
previously reported,28 as anticipated for a response with limited receptor reserve.33 We also 
assayed compounds for which we had membrane competition binding data spanning a range 
of affinities, including analogues of 1229U91, I and J (Figure 5E; Table 3)29 and some 
unlabeled BVD-15 analogues K – N (Table 3) and found the same trends (Table 4, Figure 
S3). 
Table 3: Analytical data of dimeric 1229U91 analogues and other unlabelled BVD-15 analogues. 
Code Sequence MW 
(Calc.) 
ESI-MS m/z LC/MS 
RT. (min)c 
HPLC 
purity (%) 
Ref. 
I Bis(Lys4)1229U91 2436.9 851.6a 11.16 98 29 
J Bis(des-Ile1)1229U91 2126.4 748.1a 11.00 99 29 
K FBz-INPKYRLRY-NH2 1343.6 672.8b 12.30 97  
L INPOYRLRY-NH2 1207.4 604.7b 10.55 98 24 
M FBz-INPRF*RLRY-NH2 1506.7 754.2b 12.93 99  
N INPRF*RLRY-NH2 1384.6 693.2b 11.51 98  
a. ESI-MS base peak corresponds to [M+TFA+3H]3+. Note that [M+3H]3+ peaks were observed at 
lower intensity. 
b. ESI-MS base peak corresponds to [M+2H]2+. 
c. HPLC retention time using a Phenomenex Luna C-8 column (100Å, 3µm, 100×2.00mm). The 
gradient is composed of 100% H2O (0.1% TFA) for 4 min, 0-60% acetonitrile in H2O (0.1% TFA) 
over 10 min, and isocratic 60% acetonitrile in H2O (0.1% TFA) for 1 min.  
Detection wavelength = 214 nm. 
FBz = 4-fluorobenzoyl, O = ornithine, F* = Phe(4-CH2NH-FBz). 
Table 4: Competition binding assays at Y1R and Y4R using compound H as a competing ligand, in 
comparison to radioligand binding data. 
Peptide Y1R (pKi)a Live 
cell imaging (H) 
Y1R (pKi) [125I]PYY 
membranes 
Y4R (pKi) a Live 
cell imaging (H) 
Y4R (pKi) [125I]PP 
membranes 
NPY  7.95 ± 0.12 9.75 ± 0.16 - - 
PYY 7.67 ± 0.10 9.50 ± 0.23 - - 
Leu31,Pro34-NPY 7.82 ± 0.11 - - - 
PYY(3-36) < 6.0 - - - 
PP  < 6.0 - 8.69 ± 0.11 10.1 ± 0.2134  
BIBO3304 8.76 ± 0.04 9.25 ± 0.11 - - 
1229U91 8.80 ± 0.07 9.90 ± 0.06 7.21 ± 0.10 9.6 ± 0.1134 
I 8.35 ± 0.12 10.18 ± 0.12 7.20 ± 0.10 - 
J 6.03 ± 0.59 8.91 ± 0.08 6.91 ± 0.11 - 
K 6.48 ± 0.17 9.10 ± 0.08 - - 
L 7.69 ± 0.09 9.73 ± 0.01 - - 
M 6.23 ± 0.11 8.62 ± 0.19 - - 
N 7.59 ± 0.10 9.74 ± 0.08 - - 
a pKi estimates from n = 3-4 whole cell competition binding (H) in Y1R-GFP or Y4R-GFP cells, using the 
Cheng-Prusoff correction based on H pKD derived from saturation analysis in imaging studies. pKi estimates 
derived from [125I]PYY binding to 293TR Y1R-GFP membranes (n = 2-6) 
Compound H displayed moderate affinity for Y4R (Figure 6), with saturation binding assays 
yielding a pKD for H of 6.26 ± 0.11 (n = 4), 8 fold lower than for Y1R. It did not bind cells 
expressing Y2R or Y5R (data not shown) at up to 1 µM, as might be predicted from the reported 
selectivity profile for BVD-15.35 In contrast to its actions at the Y1R, H was a Y4R partial 
agonist, a property shared by BVD-15, in the β-arrestin2 recruitment assay (Figure 6; pEC50 = 
7.10 ± 0.19, 1 µM response 59.0 ± 3.6 %, 100 nM PP, n = 6); other cyanine BVD-15 analogues 
E-G displayed limited Y4R agonism at the highest concentration tested (1 µM). At 100 nM, H 
selectively labelled 293TR cells expressing Y4R-GFP (Figure 6A), enabling competition 
binding studies to derive pKi estimates for human PP, 1229U91 and its analogues I and J 
(Figure 6C; Table 4). As previously discussed, these estimates were lower than those 
previously reported for [125I]PP agonist binding studies in Y4R containing membranes.
34 
However, the estimates of PP and 1229U91 affinity in whole cells by this route closely 
corresponded with their potencies in the arrestin recruitment assay (PP pEC50 = 8.77 ± 0.07, n 
= 5; 1229U91 weak partial agonist pEC50 = 7.43 ± 0.41, n = 4; Figure 6D). Comparisons of 
Y1R/Y4R binding affinities of 1229U91 analogues demonstrated that I had equivalent Y1R/Y4R 
selectivity as 1229U91 (16-30 fold selective for Y1R), while removal of the terminal Ile 
residues in J, reversed the selectivity profile between these subtypes (approximately 8 fold 
higher affinity for Y4R over Y1R). 
 
Figure 6: [Lys2(sCy5), Arg4]BVD-15 (H) is also a Y4R fluorescent ligand. Panel A illustrates representative 
images of 100 nM H binding (red) to 293TR Y4R-GFP cells (green) in the absence or presence of the 
endogenous peptide PP or 1229U91. Quantification of these data obtained saturation data for H (pKD 6.26), 
in which non-specific binding was assessed in the presence of 1 M PP (Panel B, experiment representative 
of 4), and competition curves in Panel C (pooled from 4-7 experiments), from which the pKi estimates in 
Table 4 were determined. In the Y4R-β-arrestin2 recruitment assay (Panel D), H was a partial agonist 
compared to PP, but of higher relative efficacy than 1229U91 (pooled data 4-10 experiments). 
In summary, our studies of fluorescent labelling of the BVD-15 scaffold has allowed us to 
identify some new features of the peptides structure-activity relationships. First, we confirmed 
the general tolerance for modification at the 4-position, with retention of antagonistic activity 
at levels similar to the parent peptide in the presence of rhodamine derivatives and cyanine 
dyes. Second, we showed for the first time that the Asn residue at 2-position, in combination 
with introduction of an Arg at 4-position yields peptides with retained affinity. However, while 
the sulfated Cy5 (sCy5) ligand is an antagonist, the more hydrophobic Cy5.5 label has agonist 
properties. This is significant as only one other example of a truncated NPY analogue has been 
shown to be an agonist.26 We have also shown that analogue H is an excellent ligand for 
performing receptor binding studies at Y1R in intact cells using high content imaging, with low 
levels of non-specific binding. Finally, we also show that analogue H has Y4R agonism, albeit 
at a lower level of affinity compared to Y1R binding. Thus analogue H is also a suitable ligand 
for conducting competition binding and functional assays against Y4R and has been applied 
recently in structure-activity studies of the dimeric Y4 agonist, BVD-74D 
36, 37. The ready 
synthesis of this fluorescent ligand and its favourable properties will be of great utility in the 
development of new ligands for these two important receptors. 
Experimental Methods 
Material 
Nα-Fmoc protected amino acids were purchased from Auspep, Chemimpex and Mimotopes. 
Rink amide resin (0.53 meq/g, 100-200 mesh), HCTU and PyClock were obtained from 
Chemimpex. TFA, TIPS, DMB, HFIP, DIPEA, piperidine, CuSO4, aminoguanidine, sodium 
ascorbate and DMSO were purchased from Sigma-Aldrich. All solvents were obtained from 
Merck. Cyanine dyes were purchased from Lumiprobe and W&J PharmaChem. THPTA was 
a gift from Dr Bim Graham’s group (Monash Institute of Pharmaceutical Sciences, Monash 
University). The Rhodamine B derivatives were prepared in-house from the commercially 
available product (Sigma-Aldrich), according to Nguyen and Francis.27 All solvents were of 
analytical grade, and all chemicals were used without further purification. 
Molecular mass of peptides was determined by ESI-MS using a Shimadzu LCMS2020 
instrument, incorporating a Phenomenex Luna C-8 column (100Å, 3μm, 100×2.00mm). 
Detection wavelength was set at 214 nm. This system used 0.05% TFA in MilliQ water as the 
aqueous buffer, and 0.05% TFA in acetonitrile as the organic buffer. The eluting profile was a 
linear gradient of 0-60% acetonitrile in water over 10 min at 0.2 ml/min. 
Crude peptides were purified on a Phenomenex Luna C-8 column (100Å, 10μm, 250×21.2mm) 
utilising a Waters 600 semi-preparative RP-HPLC that incorporates a Waters 486 UV detector. 
Detection wavelength was set at 230 nm. This system used 0.1% TFA in MilliQ water as the 
aqueous buffer, and 0.1% TFA in acetonitrile as the organic buffer. The eluting profile was a 
linear gradient of 0-80% acetonitrile in water over 60 min at 10 ml/min. 
Peptide synthesis 
General synthesis 
Linear peptides (0.1 mmol scale) were synthesised on Rink amide resin using a 3-channel serial 
automated peptide synthesiser (“PS3”, Protein Technologies Inc.), which adopted standard 
Fmoc-based solid phase synthesis strategy. Fmoc deprotection was performed by piperidine 
(20% v/v) in DMF for 2×5 min. Fmoc protected amino acids (3 eq.) were coupled using DMF 
as solvent, and DIPEA in DMF (7% v/v) with HCTU (3 eq.) as the activating agent for 50 min.  
Protected peptidyl-resins were cleaved by treating with a cocktail (5 ml) composed of TFA-
TIPS-DMB (92.5%:2.5%:5%) for 3 h. The cleavage mixture was then filtered, concentrated by 
stream of N2, precipitated in cold Et2O and centrifuged at 3000 rpm for 5 min. The crude 
product was dissolved in water-acetonitrile mixture (50%:50%) and lyophilised. 
Labelling methods 
Method 1: The Nα-Fmoc protected linear peptide dissolved in DMF (0.6 ml) was treated with 
carboxyl-functionalised fluorophore of interest (1.2 eq.), PyClock (2 eq.) and NMM (12 eq.) 
overnight. After DMF was removed in vacuo, the product was washed by TFA (1 ml), 
precipitated by cold Et2O and centrifuged at 3000 rpm for 5 min. The N
α-Fmoc group was then 
removed by piperidine (20%) in DMF (5 ml) for 30 min and the reagents were evaporated in 
vacuo. The product was re-dissolved in water-acetonitrile (50%:50%) and lyophilised. 
Method 2: The protected peptidyl-resin containing a Lys(Mtt) residue was treated with HFIP 
(25%) and TIPS (5%) in DCM (5 ml) for 30 min to selectively remove the Mtt group. Cy5.5 
(as an N-succinimidyl ester) was conjugated by treating overnight in an alkaline condition 
created by DIPEA (10 eq.). 
Method 3: Linear peptide containing a Lys(azide) residue (15 mg) was labelled by treating with 
a mixture of RhB-alkyne (2 eq.), CuSO4 (0.5 eq.), THPTA (2.5 eq.), sodium ascorbate (25 eq.) 
and aminoguanidine (25 eq.) in a potassium phosphate buffer containing 2% DMSO, where 
the final concentration of linear peptide was 0.2 mM. The mixture was stirred for 1 h and 
lyophilised. 
Peptides were purified by RP-HPLC as described above. The purity of all peptides are ≥ 93% 
according to the HPLC chromatographs produced by the ESI-MS method described above, and 
MS data corresponded to the expected m/z values. Additional details are provided in Table 1, 
Table 3 and Supporting Information. 
 
  
Cell culture 
HEK293T and 293TR cells (Invitrogen) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma-Aldrich) supplemented with 10% foetal bovine serum, 293TR cell lines 
inducibly expressing Y1R or Y4R tagged with C-terminal GFP, and dual HEK293 cells co-
expressing Y receptor-Yc and -arrestin2-Yn (where Yc and Yn are complementary fragments 
of YFP) are as previously reported.28, 38 
[125I]PYY competition binding studies in membranes  
Competition binding assays were carried out as described previously.28, 38 Using membranes 
from the 293TR Y1R-GFP cells, competition binding assays were performed for 90 min at 
21°C in buffer (25 mM HEPES, 2.5 mM CaCl2, 1.0 mM MgCl2, 0.1 % bovine serum albumin, 
0.1 mg/ml bacitracin; pH = 7.4), increasing concentrations of unlabelled ligands (10-12 M to 
10-6 M, duplicate) and  [125I]PYY (15 pM). Non-specific binding in these experiments 
comprised less than 5% of total counts, and was subtracted from the data.   
In both sets of data, IC50 values were calculated from displacement curves (repeated 2-3 times 
for each peptide, fitted using non-linear least squares regression in GraphPad Prism v6 
(GraphPad software, San Diego CA, U.S.A). They were converted to pKi estimates using the 
Cheng-Prusoff relationship:  
𝐾𝑖 =
𝐼𝐶50
1 +
[𝑅𝐿]
𝐾𝑅𝐿
⁄
 
where [RL] and KRL represent the concentration and equilibrium dissociation constant of 
[125I]PYY respectively. 
Y receptor-β-arrestin recruitment assays 
Bimolecular fluorescence complementation (BiFC) based detection of Y receptor--arrestin2 
association was performed as described previously.28, 38. The Y receptor arrestin BiFC cell lines 
were seeded at 40,000 cells/well onto poly-D-lysine coated Greiner 655090 imaging plates, and 
experiments performed 24 hrs later. Stimulation with human NPY (Y1R) or PP (Y4R; Bachem, 
St. Helens, U.K.), or other ligands was performed in HEPES-buffered saline solution (HBSS) 
including 0.1% BSA (10-10 M-10-6 M) for 60 min at 37°C, with antagonist pre-incubations (30 
min, 37°C) if required. Incubations were terminated by fixation with 3% paraformaldehyde in 
phosphate buffered saline (PBS, 10 min at 21°C), the cells were washed once with PBS and 
the cell nuclei were stained for 15 min with H33342 (2 µg/ml in PBS, Sigma). H33342 was 
then removed by a final PBS wash. Images (4 central sites/well) were acquired automatically 
on the IX Ultra confocal platereader, using 405 nm / 488 nm laser lines for H33342 and 
complemented YFP excitation respectively. 
A granularity algorithm (MetaXpress 5.3) identified internal fluorescent compartments within 
these images of at least 3 µm diameter (range set to 3-12 µm), on the basis of granule intensity 
thresholds set with reference to the vehicle or positive plate controls (e.g. 1 µM NPY). The 
response for each data point (duplicate data) was quantified as mean granule average 
intensity/cell, normalised to the reference agonist response. Concentration response curves 
were fitted to the pooled data by non-linear least squares regression (GraphPad Prism), yielding 
estimates of agonist potency as pEC50 and maximum response (Rmax). Where appropriate, the 
Gaddum equation was used to calculate an estimate of antagonist affinity:  
𝑝𝐾𝑏 = log[𝐶𝑅 − 1] − log[𝐵] 
where CR is the concentration ratio (NPY EC50 in the presence of antagonist / control NPY 
EC50), and [B] is the antagonist concentration used. To assess NPY concentration response 
curves in the absence and presence of multiple antagonist concentrations ([Lys4]BVD-15 or 
compound H), Schild analysis was performed by global fitting of the curve families in 
GraphPad Prism; the Schild plot of log[𝐶𝑅 − 1]  versus log [B] illustrated the antagonist 
affinity estimate (pA2) as the X-intercept of the fitted line. 
Y receptor saturation and competition fluorescent ligand binding assays 
293TR Y1R-GFP or Y4R-GFP cells were seeded at 20,000 cells / well in poly-D-lysine coated 
96-well Greiner 655090 imaging plates, treated as required with 1 µg/ml tetracycline for 18-
21 hrs and then used in experiments at confluence. Incubations were performed in HBSS/0.1% 
BSA, the permeable nuclear dye H33342 (2 µg/ml, Sigma) and competitor ligands as 
appropriate (10-10 M to 10-5 M) for 2 min, prior to the addition of fluorescent ligand at the 
concentration indicated. In saturation studies, non-specific binding was assessed in the 
presence of 1 µM BIBO3304 (Y1R) or PP (Y4R). After 30 min at 37°C the media was replaced 
with HBSS/0.1% BSA and plates were immediately imaged (2 sites/well).  For cyanine 
analogues (e.g. H) an IX Ultra confocal platereader (Molecular Devices, Sunnyvale CA, 
U.S.A.) used laser excitation/emission filter settings appropriate for H33342 (DAPI), Y 
receptor-GFP (FITC), and fluorescent ligand (Cy5). For rhodamine B derivatives an IX Micro 
epifluorescence platereader (Molecular Devices) acquired the images using the TRITC 
excitation/emission filter set.   
For fluorescent ligand binding using H, bound ligand fluorescence was quantified by 
granularity analysis (2-3 µm diameter granules; MetaXpress 5.3, Molecular Devices).  
Competition data were normalised to positive (totals 100 %) and negative (0%, in presence of 
either 1 µM NPY or 100 nM PP as appropriate) controls. For saturation studies, total and non-
specific binding data were globally fitted using a one site binding model whereby: 
Total binding = 𝐵𝑚𝑎𝑥 .
[𝐹𝐿]
[𝐹𝐿]+𝐾𝐷
+ 𝑁𝑆×[𝐹𝐿] 
Non-specific binding = 𝑁𝑆×[𝐹𝐿] 
[FL] is the fluorescent ligand concentration, Bmax represents the maximum specific binding, 
NS is the gradient of the non-specific binding relationship and KD is the equilibrium 
dissociation constant for compound H. 
 pIC50 values for unlabelled ligands were then determined from the pooled data using GraphPad 
Prism, and converted to pKi using the Cheng-Prusoff relationship described above and the 
fluorescent ligand KD estimated from saturation data. In competition experiments in which 
compound H concentration [FL] in the assay was varied, the plot of BIBO3304 IC50 versus 
[FL] was fitted by linear regression using the relationship derived from the Cheng-Prusoff 
equation:  
𝐼𝐶50 =
𝐾𝑖
𝐾𝐷
×[𝐹𝐿] + 𝐾𝑖 
The Y intercept for this fit derives an estimate of Ki for the competing ligand, BIBO3304, and 
the slope (𝐾𝑖 𝐾𝐷⁄ ) also yields a further measurement of affinity of the fluorescent ligand H 
(KD). 
  
Glossary 
DCM Dichloromethane 
DIPEA N,N-diisopropylethylamine 
DMB 1,3-dimethoxybenzene 
DMF N,N-dimethylformamide 
HCTU O-(1H-6-chlorobenzotriazol-1-y1)-N,N,N',N'-tetramethyluronium  
                                           hexafluorophosphate 
 
HFIP Hexafluoroisopropanol 
NMM N-methylmorpholine 
RhB Rhodamine B 
TFA Trifluoroacetic acid 
THPTA Tris(3-hydroxypropyltriazolylmethyl)amine 
TIPS Triisopropylsilane 
Supporting Information 
Detailed synthesis procedures as well as additional supplementary figures showing dose-
response curves for Y1R binding by peptides, fluorescence excitation/emission spectra for 
compound H and HPLC profiles for synthesized peptides are provided on the Journal’s 
website. 
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